Abstract
Aim: This study investigated polymorphisms of five inflammatory-related genes for association with duloxetine and placebo response in patients with major depression. Patients & methods: Twenty SNPs in IL-1β, IL-2, IL-6, TSPO and BDNF were genotyped in major depressive disorder patients treated with either duloxetine (n = 215) or placebo (n = 235) for up to 8 weeks. Treatment response was measured with the Montgomery-Åsberg Depression Rating Scale. Results: IL-6 variants rs2066992 and rs10242595 were nominally associated with response to duloxetine (p = 0.047 and p = 0.028, respectively). Notably, the variant rs2066992 was also associated with placebo response (p = 0.026). However, none of our results remained significant after correction for multiple testing. Conclusion: Our findings tentatively suggest that IL-6 variants play a role in duloxetine and placebo response, which warrants further investigation.
Original language | English (US) |
---|---|
Pages (from-to) | 1919-1929 |
Number of pages | 11 |
Journal | Pharmacogenomics |
Volume | 16 |
Issue number | 17 |
DOIs | |
State | Published - Nov 2015 |
Externally published | Yes |
Keywords
- BDNF
- IL-6
- TSPO
- cytokines
- depression
- duloxetine
- inflammation
- placebo
- treatment response
ASJC Scopus subject areas
- Molecular Medicine
- Genetics
- Pharmacology